Brief: Poseida Therapeutics Gets FDA Clearance For Trial Of Myeloma Treatment
30/08/2021 13:20
Aug 30 (Reuters) - Poseida Therapeutics Inc PSTX.O :
* POSEIDA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR P-BCMA-ALLO1, AN ALLOGENEIC CAR-T
CANDIDATE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
* POSEIDA THERAPEUTICS - WITH P-BCMA-ALLO1 IND NOW CLEARED,
ACTIVELY FOCUSED ON OPENING CLINICAL SITES WITH INTENTION TO
BEGIN DOSING LATER THIS YEAR
Source text for Eikon: ID:nPn67708ca
Further company coverage: PSTX.O
((Reuters.Briefs@thomsonreuters.com;))